New didagnostic and therapy go hand in hand for breast cancer

Article Abstract:

Identifying patients who do not respond to tamoxifen would prevent them from undergoing ineffective treatments. Patients whose tumors produce excessive amounts of human epidermal growth factor receptor-2, or HER2 are the ones who do not respond to tamoxifen.

Science & research

---

Neurology: Oxford GlycoSciences/Pfizer

Article Abstract:

London,UK-based Oxford GlycoSciences PLC and New York, NY-based Pfizer have filed a joint patent application which describes discoveries made in their research and development collaboration in Alzheimer's disease.

Alzheimer Disease Controllers, Anti-Alzheimer's disease agents, Pfizer Corp., Oxford GlycoSciences PLC

---

Suppressor Gene: patent on p16 Tumor Suppressor Gene; rivaled only by p53

Article Abstract:

Myriad Genetics was awarded patent number 5,801,236 by the US Patent and Trademark Office for the potent tumor suppressor gene called p16 or MTSI.

Brief Article, Myriad Genetics Inc.

Similar abstracts:

• Abstracts: The latest diagnostic trend: linking the point of care to the lab. Business and strategy: global standards
• Abstracts: Mission statement content and hospital performance in the Canadian not-for-profit health care sector. Hospital governance in a competitive environment
• Abstracts: Findings of innovation research applied to quality management principles for health care. Close to a bull's eye - a concurring opinion
• Abstracts: Medicaid crowd out and the inverse Truman bind. Be creative in consumer cost-sharing for pharmaceutical benefits
• Abstracts: Infectious diseases: AMRAD: AMRAD and Becton Dickinson in alliance for rapid tests. Automation '99-a point in space

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.